The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 8, 2012, Pages 991-998

  Chiu, H Y ^a   Wang, T S ^a   Chang, C Y ^a   Tsai, T F ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; EFALIZUMAB; ETANERCEPT; ETRETIN; METHOTREXATE;

ACNE; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA AREATA; BACTERIAL ENDOCARDITIS; CELLULITIS; CHILD; COLON CANCER; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLICULITIS; GINGIVITIS; HEADACHE; HEALTH CARE FINANCING; HERPES LABIALIS; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INJECTION SITE REACTION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PARONYCHIA; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PRURITUS; PSORIASIS; QUALITY OF LIFE; REIMBURSEMENT; REMISSION; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SIDE EFFECT; STROKE; SUBJECT GLOBAL ASSESSMENT; SYSTEMIC THERAPY; TREATMENT RESPONSE; URTICARIA; WEAKNESS;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INSURANCE COVERAGE; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 84864281755     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04199.x     Document Type: Review

References (49)

1. Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
2. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
3. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-115.
4. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566.
5. Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-191.
6. Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007; 87: 335-340.
7. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 2000; 14: 267-271.
8. Kotrulja L, Tadinac M, Joki-Begi NA, et al. A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients. Acta Derm Venereol 2010; 90: 251-256.
9. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-139.
10. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152: 954-960.
11. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
12. Farhi D, Falissard B, Dupuy A,. Global assessment of psoriasis severity and change from photographs: a valid and consistent method. J Invest Dermatol 2008; 128: 2198-2203.
13. Pink AE, Fonia A, Allen MH, et al. Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 2010; 162: 780-785.
14. Wu JJ, Tsai TF,. Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis. Arch Dermatol 2008; 144: 1403-1404.
15. He GY, Tsai TF,. Concomitant occurrence of acne, alopecia areata, and urticarial eruption during treatment of adalimumab in a patient with pustulosispalmoplantaris: a case report and literature review. Dermatologica Sinica In press.
16. Chiu HY, Hsueh PR, Tsai TF,. Clinical experience of QuantiFERON((R))-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011; 164: 553-559.
17. Wolfe F, Michaud K,. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56: 2886-2895.
18. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005; 64: 1421-1426.
19. Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol 2009; 160: 162-169.
20. Driessen RJ, Boezeman JB, van de Kerkhof PC, et al. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
21. Foley P, Quirk C, Sullivan J, et al. Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence. J Eur Acad Dermatol Venereol 2010; 24: 1135-1143.
22. Woolf RT, Smith CH, Robertson K, et al. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol 2010; 163: 889-892.
23. Ryan C, Kirby B, Collins P, et al. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 2009; 34: 784-788.
24. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004; 50: 859-866.
25. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 10-16.
26. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-972.
27. O'Neill P, Kelly P,. Postal questionnaire study of disability in the community associated with psoriasis. BMJ 1996; 313: 919-921.
28. Schmitt J, Wozel G,. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005; 210: 194-199.
29. Sato R, Milligan G, Molta C, et al. Health-related quality of life and healthcare resource use in European patients with plaque psoriasis: an association independent of observed disease severity. Clin Exp Dermatol 2011; 36: 24-28.
30. Feldman SR, Nijsten T, Margolis DJ, et al. Systemic therapy does not usually clear psoriasis, but treatment success does not require clearing. J Am Acad Dermatol 2005; 52: 140-141.
31. Delfino M Jr, Holt EW, Taylor CR, et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriasis: a pilot study. J Am Acad Dermatol 2008; 59: 439-47.
32. Schafer I, Hacker J, Rustenbach SJ, et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20: 62-67.
33. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43: 281-285.
34. Heydendael VM, de Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004; 9: 131-135.
35. Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009; 23: 1394-1397.
36. Brocq O, Millasseau E, Albert C, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009; 76: 350-355.
37. Du Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-568.
38. Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011; 164: 434-441.
39. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
40. Costenbader KH, Glass R, Cui J, et al. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006; 296: 2201 (author reply 3-4).
41. Callegari PE, Schaible TF, Boscia JA,. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006; 296: 2202 (author reply 3-4).
42. Okada SK, Siegel JN,. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006; 296: 2201-2202 (author reply 3-4).
43. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 889-894.
44. van de Kerkhof PC, Kragballe K, Austad J, et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006; 16: 167-171.
45. Christophers E, Griffiths CE, Gaitanis G, et al. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol 2006; 20: 921-925.
46. Shear NH,. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability? Drug Saf 2006; 29: 49-66.
47. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49: 1368-1375.
48. Lundberg L, Johannesson M, Silverdahl M, et al. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol 1999; 141: 1067-1075.
49. Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.